Cannabix Technologies Announces Detection of Methamphetamine and Amphetamine in Human Breath

Cannabix Technologies Announces Detection of Methamphetamine and Amphetamine in Human Breath

Methamphetamine & Amphetamine Detection in Breath Represents a Significant New Opportunity for Cannabix Technologies Inc.

Cannabix Technologies Inc. VANCOUVER, British Columbia, July 02, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing technologies for workplace safety and law enforcement, announces the detection of methamphetamine and amphetamine compounds in human breath samples tested with the Cannabix Marijuana Breath Test (“MBT”). Human breath samples were collected using the Cannabix Breath Collection Unit (“BCU”) (Figure 1) and were analyzed by Omega Laboratories Inc. (“Omega”) utilizing liquid chromatography-mass spectrometry ("LC-MS").

Methamphetamine & Amphetamine Detection in Breath Represents a Significant New Opportunity The detection of methamphetamine and amphetamine compounds in breath is a significant new development that further validates the sensitivity and performance of the Cannabix MBT (consisting of the Cannabix BCU, disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega). Amphetamine-class stimulants are generally present in breath at extremely low concentrations, making reliable capture and laboratory identification technically challenging. Unlike conventional biological matrices such as urine, breath contains only trace amounts of non-volatile drug compounds carried within microscopic aerosol particles originating from the respiratory tract. The Company believes these findings support the potential expansion of the Cannabix MBT beyond THC. The ability to identify amphetamine-class stimulants in breath, alongside a legally defensible chain of custody and analytical pro...